Table of Contents Author Guidelines Submit a Manuscript
Clinical and Developmental Immunology
Volume 2008, Article ID 628963, 10 pages
http://dx.doi.org/10.1155/2008/628963
Review Article

Neonatal and Infantile Immune Responses to Encapsulated Bacteria and Conjugate Vaccines

Department of Pediatric Infectious Diseases and Immunology, Wilhelmina Children's Hospital, University Medical Centre, Room KE4.133.1, P.O. Box 85090, 3508 AB Utrecht, The Netherlands

Received 22 March 2008; Revised 25 June 2008; Accepted 1 August 2008

Academic Editor: Michel Goldman

Copyright © 2008 Peter Klein Klouwenberg and Louis Bont. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. World Health Organization, “Maternal Health and Safe Motherhood Programme,” MSM96.7, 1996.
  2. The WHO Young Infants Study Group, “Conclusions from the WHO multicenter study of serious infections in young infants,” Pediatric Infectious Disease Journal, vol. 18, no. 10, supplement, pp. S32–S34, 1999. View at Publisher · View at Google Scholar
  3. D. Thomas-Rudolph, T. W. Du Clos, C. M. Snapper, and C. Mold, “C-reactive protein enhances immunity to Streptococcus pneumoniae by targeting uptake to FcγR on dendritic cells,” The Journal of Immunology, vol. 178, no. 11, pp. 7283–7291, 2007. View at Google Scholar
  4. H. Jakobsen, S. Hannesdottir, S. P. Bjarnarson et al., “Early life T Cell responses to pneumucoccal conjugates increase with age and determine the polysaccharide-specific antibody response and protective efficacy,” European Journal of Immunology, vol. 36, no. 2, pp. 287–295, 2006. View at Publisher · View at Google Scholar · View at PubMed
  5. G. T. Rijkers, E. A. M. Sanders, M. A. Breukels, and B. J. M. Zegers, “Infant B cell responses to polysaccharide determinants,” Vaccine, vol. 16, no. 14-15, pp. 1396–1400, 1998. View at Publisher · View at Google Scholar
  6. S. Bondada, H.-J. Wu, D. A. Robertson, and R. L. Chelvarajan, “Accessory cell defect in unresponsiveness of neonates and aged to polysaccharide vaccines,” Vaccine, vol. 19, no. 4-5, pp. 557–565, 2000. View at Publisher · View at Google Scholar
  7. D. E. Mosier, J. J. Mond, and E. A. Goldings, “The ontogeny of thymic independent antibody responses in vitro in normal mice and mice with an X-linked B cell defect,” The Journal of Immunology, vol. 119, no. 6, pp. 1874–1878, 1977. View at Google Scholar
  8. J. J. Mond, A. Lees, and C. M. Snapper, “T cell-independent antigens type 2,” Annual Review of Immunology, vol. 13, no. 1, pp. 655–692, 1995. View at Publisher · View at Google Scholar · View at PubMed
  9. J. J. Mond, Q. Vos, A. Lees, and C. M. Snapper, “T cell independent antigens,” Current Opinion in Immunology, vol. 7, no. 3, pp. 349–354, 1995. View at Publisher · View at Google Scholar
  10. S. R. Yan, D. M. Byers, and R. Bortolussi, “Role of protein tyrosine kinase p53/56lyn in diminished lipopolysaccharide priming of formylmethionylleucyl- phenylalanine-induced superoxide production in human newborn neutrophils,” Infection and Immunity, vol. 72, no. 11, pp. 6455–6462, 2004. View at Publisher · View at Google Scholar · View at PubMed
  11. O. Levy, R. B. Sisson, J. Kenyon, E. Eichenwald, A. B. Macone, and D. Goldmann, “Enhancement of neonatal innate defense: effects of adding an N-terminal recombinant fragment of bactericidal/permeability-increasing protein on growth and tumor necrosis factor-inducing activity of gram-negative bacteria tested in neonatal cord blood ex vivo,” Infection and Immunity, vol. 68, no. 9, pp. 5120–5125, 2000. View at Publisher · View at Google Scholar
  12. G. T. Rijkers, L. A. M. Sanders, and B. J. M. Zegers, “Anti-capsular polysaccharide antibody deficiency states,” Immunodeficiency, vol. 5, no. 1, pp. 1–21, 1993. View at Google Scholar
  13. P. F. Wright and P. F. Wright, “Infectious diseases in early life in industrialized countries,” Vaccine, vol. 16, no. 14-15, pp. 1355–1359, 1998. View at Publisher · View at Google Scholar
  14. J. Kovarik and C.-A. Siegrist, “Optimization of vaccine responses in early life: the role of delivery systems and immunomodulators,” Immunology & Cell Biology, vol. 76, no. 3, pp. 222–236, 1998. View at Publisher · View at Google Scholar
  15. M. Pihlgren, M. Friedli, C. Tougne, A.-F. Rochat, P.-H. Lambert, and C.-A. Siegrist, “Reduced ability of neonatal and early-life bone marrow stromal cells to support plasmablast survival,” The Journal of Immunology, vol. 176, no. 1, pp. 165–172, 2006. View at Google Scholar
  16. C. L. Trotter, N. J. Andrews, E. B. Kaczmarski, E. Miller, and M. E. Ramsay, “Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction,” The Lancet, vol. 364, no. 9431, pp. 365–367, 2004. View at Publisher · View at Google Scholar · View at PubMed
  17. W. Timens, A. Boes, T. Rozeboom-Uiterwijk, and S. Poppema, “Immaturity of the human splenic marginal zone in infancy. Possible contribution to the deficient infant immune response,” The Journal of Immunology, vol. 143, no. 10, pp. 3200–3206, 1989. View at Google Scholar
  18. B. J. M. Zegers, M. Van Der Giessen, E. E. Reerink-Brongers, and J. W. Stoop, “The serum IgG subclass levels in healthy infants of 13–62 weeks of age,” Clinica Chimica Acta, vol. 101, no. 2-3, pp. 265–269, 1980. View at Publisher · View at Google Scholar
  19. N. Kutukculer, N. E. Karaca, O. Demircioglu, and G. Aksu, “Increases in serum immunoglobulins to age-related normal levels in children with IgA and/or IgG subclass deficiency,” Pediatric Allergy and Immunology, vol. 18, no. 2, pp. 167–173, 2007. View at Publisher · View at Google Scholar · View at PubMed
  20. D. J. Barrett and E. M. Ayoub, “IgG2 subclass restriction of antibody to pneumococcal polysaccharides,” Clinical and Experimental Immunology, vol. 63, no. 1, pp. 127–134, 1986. View at Google Scholar
  21. E. Castagnola and F. Fioredda, “Prevention of life-threatening infections due to encapsulated bacteria in children with hyposplenia or asplenia: a brief review of current recommendations for practical purposes,” European Journal of Haematology, vol. 71, no. 5, pp. 319–326, 2003. View at Publisher · View at Google Scholar
  22. T. V. Adamkiewicz, B. J. Silk, J. Howgate et al., “Effectiveness of the 7-valent pneumococcal conjugate vaccine in children with sickle cell disease in the first decade of life,” Pediatrics, vol. 121, no. 3, pp. 562–569, 2008. View at Publisher · View at Google Scholar · View at PubMed
  23. D. E. Mosier, I. M. Zitron, J. J. Mond, A. Ahmed, I. Scher, and W. E. Paul, “Surface immunoglobulin D as a functional receptor for a subclass of B lymphocytes,” Immunological Reviews, vol. 37, no. 1, pp. 89–104, 1977. View at Google Scholar
  24. P. Balogh, Y. Aydar, J. G. Tew, and A. K. Szakal, “Ontogeny of the follicular dendritic cell phenotype and function in the postnatal murine spleen,” Cellular Immunology, vol. 214, no. 1, pp. 45–53, 2001. View at Publisher · View at Google Scholar · View at PubMed
  25. A. Lanoue, M. R. Clatworthy, P. Smith et al., “SIGN-R1 contributes to protection against lethal pneumococcal infection in mice,” Journal of Experimental Medicine, vol. 200, no. 11, pp. 1383–1393, 2004. View at Publisher · View at Google Scholar · View at PubMed
  26. E. A. Koppel, M. Litjens, V. C. van den Berg, Y. van Kooyk, and T. B. H. Geijtenbeek, “Interaction of SIGNR1 expressed by marginal zone macrophages with marginal zone B cells is essential to early IgM responses against Streptococcus pneumoniae,” Molecular Immunology, vol. 45, no. 10, pp. 2881–2887, 2008. View at Publisher · View at Google Scholar · View at PubMed
  27. M.-J.P. Llopis, G. Harms, M. J. Hardonk, and W. Timens, “Human immune response to pneumococcal polysaccharides: complement-mediated localization preferentially on CD21-positive splenic marginal zone B cells and follicular dendritic cells,” Journal of Allergy and Clinical Immunology, vol. 97, no. 4, pp. 1015–1024, 1996. View at Publisher · View at Google Scholar
  28. A. W. Griffioen, S. W. Franklin, B. J. M. Zegers, and G. T. Rijkers, “Expression and functional characteristics of the complement receptor type 2 on adult and neonatal B lymphocytes,” Clinical Immunology and Immunopathology, vol. 69, no. 1, pp. 1–8, 1993. View at Publisher · View at Google Scholar
  29. C. A. Davis, E. H. Vallota, and J. Forristal, “Serum complement levels in infancy: age related changes,” Pediatric Research, vol. 13, no. 9, pp. 1043–1046, 1979. View at Google Scholar
  30. M. A. Breukels, A. Zandvoort, G. T. Rijkers et al., “Complement dependency of splenic localization of pneumococcal polysaccharide and conjugate vaccines,” Scandinavian Journal of Immunology, vol. 61, no. 4, pp. 322–328, 2005. View at Publisher · View at Google Scholar · View at PubMed
  31. L. J. Kobrynski, A. O. Sousa, A. J. Nahmias, and F. K. Lee, “Cutting edge: antibody production to pneumococcal polysaccharides requires CD1 molecules and CD8+ cells,” The Journal of Immunology, vol. 174, no. 4, pp. 1787–1790, 2005. View at Google Scholar
  32. R. L. Chelvarajan, N. L. Gilbert, and S. Bondada, “Neonatal murine B lymphocytes respond to polysaccharide antigens in the presence of IL-1 and IL-6,” The Journal of Immunology, vol. 161, no. 7, pp. 3315–3324, 1998. View at Google Scholar
  33. D. F. Angelone, M. R. Wessels, M. Coughlin et al., “Innate immunity of the human newborn is polarized toward a high ratio of IL-6/TNF-α production in vitro and in vivo,” Pediatric Research, vol. 60, no. 2, pp. 205–209, 2006. View at Publisher · View at Google Scholar · View at PubMed
  34. R. L. Chelvarajan, S. M. Collins, I. E. Doubinskaia et al., “Defective macrophage function in neonates and its impact on unresponsiveness of neonates to polysaccharide antigens,” Journal of Leukocyte Biology, vol. 75, no. 6, pp. 982–994, 2004. View at Publisher · View at Google Scholar · View at PubMed
  35. L. Chelvarajan, D. Popa, Y. Liu, T. V. Getchell, A. J. Stromberg, and S. Bondada, “Molecular mechanisms underlying anti-inflammatory phenotype of neonatal splenic macrophages,” Journal of Leukocyte Biology, vol. 82, no. 2, pp. 403–416, 2007. View at Publisher · View at Google Scholar · View at PubMed
  36. G. J. Nossal, “Cellular mechanisms of immunologic tolerance,” Annual Review of Immunology, vol. 1, no. 1, pp. 33–62, 1983. View at Publisher · View at Google Scholar · View at PubMed
  37. S. Kurikka, H. Käyhty, L. Saarinen, P.-R. Ronnberg, J. Eskola, and P. H. Makela, “Immunologic priming by one dose of Haemophilus influenzae type b conjugate vaccine in infancy,” The Journal of Infectious Diseases, vol. 172, no. 5, pp. 1268–1272, 1995. View at Google Scholar
  38. J. Eskola and H. Käyhty, “Early immunization with conjugate vaccines,” Vaccine, vol. 16, no. 14-15, pp. 1433–1438, 1998. View at Publisher · View at Google Scholar
  39. J. Eskola, J. Ward, R. Dagan, D. Goldblatt, F. Zepp, and C.-A. Siegrist, “Combined vaccination of Haemophilus influenzae type b conjugate and diphtheria-tetanus-pertussis containing acellular pertussis,” The Lancet, vol. 354, no. 9195, pp. 2063–2068, 1999. View at Publisher · View at Google Scholar
  40. B. Adkins, C. Leclerc, and S. Marshall-Clarke, “Neonatal adaptive immunity comes of age,” Nature Reviews Immunology, vol. 4, no. 7, pp. 553–564, 2004. View at Publisher · View at Google Scholar · View at PubMed
  41. S. P. Bjarnarson, H. Jakobsen, G. Del Giudice, E. Trannoy, C.-A. Siegrist, and I. Jonsdottir, “The advantage of mucosal immunization for polysaccharide-specific memory responses in early life,” European Journal of Immunology, vol. 35, no. 4, pp. 1037–1045, 2005. View at Publisher · View at Google Scholar · View at PubMed
  42. R. Booy, P. T. Heath, P. E. M. Slack, N. Begg, and E. R. Moxon, “Vaccine failures after primary immunisation with Haemophilus influenzae type-b conjugate vaccine without booster,” The Lancet, vol. 349, no. 9060, pp. 1197–1202, 1997. View at Publisher · View at Google Scholar
  43. G. S. Ribeiro, J. B. T. Lima, J. N. Reis et al., “Haemophilus influenzae meningitis 5 years after introduction of the Haemophilus influenzae type b conjugate vaccine in Brazil,” Vaccine, vol. 25, no. 22, pp. 4420–4428, 2007. View at Publisher · View at Google Scholar · View at PubMed
  44. M. L. Barbour, R. T. Mayon-White, C. Coles, D. W. M. Crook, and E. R. Moxon, “The impact of conjugate vaccine on carriage of Haemophilus influenzae type b,” The Journal of Infectious Diseases, vol. 171, no. 1, pp. 93–98, 1995. View at Google Scholar
  45. P. H. Mäkelä, H. Peltola, H. Käyhty et al., “Polysaccharide vaccines of group A Neisseria meningtitidis and Haemophilus influenzae type b: a field trial in Finland,” The Journal of Infectious Diseases, vol. 136, pp. S43–S50, 1977. View at Google Scholar
  46. H. Peltola, “Meningococcal vaccines. Current status and future possibilities,” Drugs, vol. 55, no. 3, pp. 347–366, 1998. View at Google Scholar
  47. L. O. Conterno, C. R. Silva Filho, J. U. Rüggeberg, and P. T. Heath, “Conjugate vaccines for preventing meningococcal C meningitis and septicaemia,” Cochrane Database of Systematic Reviews, no. 3, Article ID CD001834, 2006. View at Publisher · View at Google Scholar · View at PubMed
  48. A. Larrauri, R. Cano, M. García, and S. de Mateo, “Impact and effectiveness of meningococcal C conjugate vaccine following its introduction in Spain,” Vaccine, vol. 23, no. 32, pp. 4097–4100, 2005. View at Publisher · View at Google Scholar · View at PubMed
  49. J. Findlow, S. Taylor, A. Aase et al., “Comparison and correlation of Neisseria meningitidis serogroup B immunologic assay results and human antibody responses following three doses of the Norwegian meningococcal outer membrane vesicle vaccine MenBvac,” Infection and Immunity, vol. 74, no. 8, pp. 4557–4565, 2006. View at Publisher · View at Google Scholar · View at PubMed
  50. H. Nókleby, P. Aavitsland, J. O'Hallahan, B. Feiring, S. Tilman, and P. Oster, “Safety review: two outer membrane vesicle (OMV) vaccines against systemic Neisseria meningitidis serogroup B disease,” Vaccine, vol. 25, no. 16, pp. 3080–3084, 2007. View at Publisher · View at Google Scholar · View at PubMed
  51. M.-C. Demachy, V. Vernet-Garnier, J. Cottin et al., “Antimicrobial resistance data on 16,756 Streptococcus pneumoniae isolates in 1999: a pan-regional multicenter surveillance study in France,” Microbial Drug Resistance, vol. 11, no. 4, pp. 323–329, 2005. View at Publisher · View at Google Scholar · View at PubMed
  52. G. B. Lesinski and M. A. Westerink, “Vaccines against polysaccharide antigens,” Current Drug Targets—Infectious Disorders, vol. 1, no. 3, pp. 325–334, 2001. View at Google Scholar
  53. “Pneumococcal conjugate vaccine for childhood immunization—WHO position paper,” Weekly Epidemiological Record, vol. 82, no. 12, pp. 93–104, 2007.
  54. “Study Evaluating 13-Valent Pneumococcal Conjugate Vaccine Catch-Up Regimens in Older Infants and Children,” April 2008, http://www.clinicaltrials.gov/.
  55. “Safety and Immunogenicity Study of a Booster Dose of GSK Biologicals' 10-Valent Pneumococcal Conjugate Vaccine,” April 2008, http://www.clinicaltrials.gov/.
  56. S. Black, H. Shinefield, B. Fireman et al., “Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children,” Pediatric Infectious Disease Journal, vol. 19, no. 3, pp. 187–195, 2000. View at Publisher · View at Google Scholar
  57. C. G. Grijalva, J. P. Nuorti, P. G. Arbogast, S. W. Martin, K. M. Edwards, and M. R. Griffin, “Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysis,” The Lancet, vol. 369, no. 9568, pp. 1179–1186, 2007. View at Publisher · View at Google Scholar · View at PubMed
  58. C. J. Tsai, M. R. Griffin, J. P. Nuorti, and C. G. Grijalva, “Changing epidemiology of pneumococcal meningitis after the introduction of pneumococcal conjugate vaccine in the United States,” Clinical Infectious Diseases, vol. 46, no. 11, pp. 1664–1672, 2008. View at Publisher · View at Google Scholar · View at PubMed
  59. J. Eskola, T. Kilpi, A. Palmu et al., “Efficacy of a pneumococcal conjugate vaccine against acute otitis media,” The New England Journal of Medicine, vol. 344, no. 6, pp. 403–409, 2001. View at Publisher · View at Google Scholar · View at PubMed
  60. F. Michon, C. Uitz, A. Sarkar et al., “Group B streptococcal type II and III conjugate vaccines: physicochemical properties that influence immunogenicity,” Clinical and Vaccine Immunology, vol. 13, no. 8, pp. 936–943, 2006. View at Publisher · View at Google Scholar · View at PubMed
  61. F. Y. C. Lin, V. A. Ho, H. B. Khiem et al., “The efficacy of a Salmonella typhi Vi conjugate vaccine in two-to-five-year-old children,” The New England Journal of Medicine, vol. 344, no. 17, pp. 1263–1269, 2001. View at Publisher · View at Google Scholar
  62. S. J. Cryz, Jr., J. O. Que, A. S. Cross, and E. Fürer, “Synthesis and characterization of a polyvalent Escherichia coli O-polysaccharide-toxin A conjugate vaccine,” Vaccine, vol. 13, no. 5, pp. 449–453, 1995. View at Publisher · View at Google Scholar
  63. T. Tollersrud, L. Zernichow, S. R. Andersen, K. Kenny, and A. Lund, “Staphylococcus aureus capsular polysaccharide type 5 conjugate and whole cell vaccines stimulate antibody responses in cattle,” Vaccine, vol. 19, no. 28-29, pp. 3896–3903, 2001. View at Publisher · View at Google Scholar
  64. R. J. Singleton, T. W. Hennessy, L. R. Bulkow et al., “Invasive pneumococcal disease caused by nonvaccine serotypes among Alaska Native children with high levels of 7-valent pneumococcal conjugate vaccine coverage,” The Journal of the American Medical Association, vol. 297, no. 16, pp. 1784–1792, 2007. View at Publisher · View at Google Scholar · View at PubMed
  65. J. Eskola, H. Peltola, and A. K. Takala, “Efficacy of Haemophilus influenzae type b polysaccharide-diphtheria toxoid conjugate vaccine in infancy,” The New England Journal of Medicine, vol. 317, no. 12, pp. 717–722, 1987. View at Google Scholar
  66. D. F. Kelly, E. R. Moxon, and A. J. Pollard, “Haemophilus influenzae type b conjugate vaccines,” Immunology, vol. 113, no. 2, pp. 163–174, 2004. View at Publisher · View at Google Scholar · View at PubMed
  67. C. L. Yeh, D. F. Kelly, L.-M. Yu et al., “Haemophilus influenzae type b vaccine failure in children is associated with inadequate production of high-quality antibody,” Clinical Infectious Diseases, vol. 46, no. 2, pp. 186–192, 2008. View at Publisher · View at Google Scholar · View at PubMed
  68. J. McVernon, N. Andrews, M. P. E. Slack, and M. E. Ramsay, “Risk of vaccine failure after Haemophilus influenzae type b (Hib) combination vaccines with acellular pertussis,” The Lancet, vol. 361, no. 9368, pp. 1521–1523, 2003. View at Publisher · View at Google Scholar
  69. N. R. E. Kitchin, J. Southern, R. Morris et al., “Evaluation of a diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae type b vaccine given concurrently with meningococcal group C conjugate vaccine at 2, 3 and 4 months of age,” Archives of Disease in Childhood, vol. 92, no. 1, pp. 11–16, 2007. View at Publisher · View at Google Scholar · View at PubMed
  70. H.-J. Schmitt, G. Maechler, P. Habermehl et al., “Immunogenicity, reactogenicity, and immune memory after primary vaccination with a novel Haemophilus influenzae-Neisseria meningitidis serogroup C conjugate vaccine,” Clinical and Vaccine Immunology, vol. 14, no. 4, pp. 426–434, 2007. View at Publisher · View at Google Scholar · View at PubMed
  71. S. Gatchalian, E. Palestroque, I. De Vleeschauwer et al., “The development of a new heptavalent diphtheria-tetanus-whole cell pertussis-hepatitis B-Haemophilus influenzae type b-Neisseria meningitidis serogroups A and C vaccine: a randomized dose-ranging trial of the conjugate vaccine components,” International Journal of Infectious Diseases, vol. 12, no. 3, pp. 278–288, 2008. View at Publisher · View at Google Scholar · View at PubMed
  72. E. Vidor, A. Hoffenbach, and M. A. Fletcher, “Haemophilus influenzae type b vaccine: reconstitution of lyophilised PRP-T vaccine with a pertussis-containing paediatric combination vaccine, or a change in the primary series immunisation schedule, may modify the serum anti-PRP antibody responses,” Current Medical Research and Opinion, vol. 17, no. 3, pp. 197–209, 2001. View at Publisher · View at Google Scholar
  73. F. A. Wyle, M. S. Artenstein, B. L. Brandt et al., “Immunologic response of man to group B meningococcal polysaccharide vaccines,” The Journal of Infectious Diseases, vol. 126, no. 5, pp. 514–521, 1972. View at Google Scholar
  74. S. J. N. Devi, W. D. Zollinger, P. J. Snoy et al., “Preclinical evaluation of group B Neisseria meningitidis and Escherichia coli K92 capsular polysaccharide-protein conjugate vaccines in juvenile rhesus monkeys,” Infection and Immunity, vol. 65, no. 3, pp. 1045–1052, 1997. View at Google Scholar
  75. C. Auckland, S. Gray, R. Borrow et al., “Clinical and immunologic risk factors for meningococcal C conjugate vaccine failure in the United Kingdom,” The Journal of Infectious Diseases, vol. 194, no. 12, pp. 1745–1752, 2006. View at Publisher · View at Google Scholar · View at PubMed
  76. G. Blanchard Rohner, M. D. Snape, D. F. Kelly et al., “The magnitude of the antibody and memory B cell responses during priming with a protein-polysaccharide conjugate vaccine in human infants is associated with the persistence of antibody and the intensity of booster response,” The Journal of Immunology, vol. 180, no. 4, pp. 2165–2173, 2008. View at Google Scholar
  77. I. Tichmann-Schumann, P. Soemantri, U. Behre et al., “Immunogenicity and reactogenicity of four doses of diphtheria-tetanus-three-component acellular pertussis-hepatitis B-inactivated polio virus-Haemophilus influenzae type b vaccine coadministered with 7-valent pneumococcal conjugate vaccine,” Pediatric Infectious Disease Journal, vol. 24, no. 1, pp. 70–77, 2005. View at Publisher · View at Google Scholar
  78. M. H. Kyaw, R. Lynfield, W. Schaffner et al., “Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae,” The New England Journal of Medicine, vol. 354, no. 14, pp. 1455–1463, 2006. View at Publisher · View at Google Scholar · View at PubMed
  79. R. Veenhoven, D. Bogaert, C. Uiterwaal et al., “Effect of conjugate pneumococcal vaccine followed by polysaccharide pneumococcal vaccine on recurrent acute otitis media: a randomised study,” The Lancet, vol. 361, no. 9376, pp. 2189–2195, 2003. View at Publisher · View at Google Scholar · View at PubMed
  80. J. Bernatoniene and A. Finn, “Advances in pneumococcal vaccines advantages for infants and children,” Drugs, vol. 65, no. 2, pp. 229–255, 2005. View at Publisher · View at Google Scholar
  81. T. Nieminen, J. Eskola, and H. Käyhty, “Pneumococcal conjugate vaccination in adults: circulating antibody secreting cell response and humoral antibody responses in saliva and in serum,” Vaccine, vol. 16, no. 6, pp. 630–636, 1998. View at Publisher · View at Google Scholar
  82. A. Nurkka, H. Ahman, M. Korkeila, V. Jantti, H. Käyhty, and J. Eskola, “Serum and salivary anti-capsular antibodies in infants and children immunized with the heptavalent pneumococcal conjugate vaccine,” Pediatric Infectious Disease Journal, vol. 20, no. 1, pp. 25–33, 2001. View at Publisher · View at Google Scholar
  83. A. Marchant and M. Newport, “Prevention of infectious disease by neonatal and early infantile immunization: prospects for the new millennium,” Current Opinion in Infectious Diseases, vol. 13, no. 3, pp. 241–246, 2000. View at Google Scholar
  84. N. Cohen, M. Stolarsky-Bennun, H. Amir-Kroll et al., “Pneumococcal capsular polysaccharide is immunogenic when present on the surface of macrophages and dendritic cells: TLR4 signaling induced by a conjugate vaccine or by lipopolysaccharide is conducive,” The Journal of Immunology, vol. 180, no. 4, pp. 2409–2418, 2008. View at Google Scholar
  85. O. Levy, E. E. Suter, R. L. Miller, and M. R. Wessels, “Unique efficacy of Toll-like receptor 8 agonists in activating human neonatal antigen-presenting cells,” Blood, vol. 108, no. 4, pp. 1284–1290, 2006. View at Publisher · View at Google Scholar · View at PubMed
  86. R. S. Chu, T. Mccool, N. S. Greenspan, J. R. Schreiber, and C. V. Harding, “CpG oligodeoxynucleotides act as adjuvants for pneumococcal polysaccharide-protein conjugate vaccines and enhance antipolysaccharide immunoglobulin G2a (IgG2a) and IgG3 antibodies,” Infection and Immunity, vol. 68, no. 3, pp. 1450–1456, 2000. View at Publisher · View at Google Scholar
  87. S. Konen-Waisman, M. Fridkin, and I. R. Cohen, “Self and foreign 60-kilodalton heat shock protein T cell epitope peptides serve as immunogenic carriers for a T cell-independent sugar antigen,” The Journal of Immunology, vol. 154, no. 11, pp. 5977–5985, 1995. View at Google Scholar
  88. H. Amir-Kroll, L. Riveron, M. E. Sarmiento, G. Sierra, A. Acosta, and I. R. Cohen, “A conjugate vaccine composed of a heat shock protein 60 T-cell epitope peptide (p458) and Neisseria meningitidis type B capsular polysaccharide,” Vaccine, vol. 24, no. 42-43, pp. 6555–6563, 2006. View at Publisher · View at Google Scholar · View at PubMed
  89. H. Jakobsen, S. Bjarnarson, G. Del Giudice, M. Moreau, C.-A. Siegrist, and I. Jonsdottir, “Intranasal immunization with pneumococcal conjugate vaccines with LT-K63, a nontoxic mutant of heat-labile enterotoxin, as adjuvant rapidly induces protective immunity against lethal pneumococcal infections in neonatal mice,” Infection and Immunity, vol. 70, no. 3, pp. 1443–1452, 2002. View at Publisher · View at Google Scholar
  90. B. C. Baudner, J. C. Verhoef, M. M. Giuliani et al., “Protective immune responses to meningococcal C conjugate vaccine after intranasal immunization of mice with the LTK63 mutant plus chitosan or trimethyl chitosan chloride as novel delivery platform,” Journal of Drug Targeting, vol. 13, no. 8-9, pp. 489–498, 2005. View at Publisher · View at Google Scholar · View at PubMed
  91. A. Sabirov and D. W. Metzger, “Intranasal vaccination of neonatal mice with polysaccharide conjugate vaccine for protection against pneumococcal otitis media,” Vaccine, vol. 24, no. 27-28, pp. 5584–5592, 2006. View at Publisher · View at Google Scholar · View at PubMed
  92. M. T. De Magistris, “Mucosal delivery of vaccine antigens and its advantages in pediatrics,” Advanced Drug Delivery Reviews, vol. 58, no. 1, pp. 52–67, 2006. View at Publisher · View at Google Scholar · View at PubMed
  93. S. Rapola, V. Jantti, R. Haikala et al., “Natural development of antibodies to pneumococcal surface protein A, pneumococcal surface adhesin A, and pneumolysin in relation to pneumococcal carriage and acute otitis media,” The Journal of Infectious Diseases, vol. 182, no. 4, pp. 1146–1152, 2000. View at Publisher · View at Google Scholar
  94. A. Virolainen, W. Russell, M. J. Crain, S. Rapola, H. Käyhty, and D. E. Briles, “Human antibodies to pneumococcal surface protein A in health and disease,” Pediatric Infectious Disease Journal, vol. 19, no. 2, pp. 134–138, 2000. View at Publisher · View at Google Scholar
  95. K. E. Morrison, D. Lake, J. Crook et al., “Confirmation of psaA in all 90 serotypes of Streptococcus pneumoniae by PCR and potential of this assay for identification and diagnosis,” Journal of Clinical Microbiology, vol. 38, no. 1, pp. 434–437, 2000. View at Google Scholar
  96. M. C. Lawrence, P. A. Pilling, V. C. Epa, A. M. Berry, A. D. Ogunniyi, and J. C. Paton, “The crystal structure of pneumococcal surface antigen PsaA reveals a metal-binding site and a novel structure for a putative ABC-type binding protein,” Structure, vol. 6, no. 12, pp. 1553–1561, 1998. View at Publisher · View at Google Scholar
  97. A. Weintraub, “Immunology of bacterial polysaccharide antigens,” Carbohydrate Research, vol. 338, no. 23, pp. 2539–2547, 2003. View at Publisher · View at Google Scholar
  98. T. Kieber-Emmons, B. Monzavi-Karbassi, B. Wang, P. Luo, and D. B. Weiner, “Cutting edge: DNA immunization with minigenes of carbohydrate mimotopes induce functional anti-carbohydrate antibody response,” The Journal of Immunology, vol. 165, no. 2, pp. 623–627, 2000. View at Google Scholar